The views and opinions expressed herein are those of the author and do not necessarily reflect those of BehaveNet, Inc.


For the first time since the launch debacle of Clozapine REMS in the fall of 2015 a representative at the call center admitted to me in a call this morning that she works for (presumably a division of) McKesson Pharmaceuticals. Now, will the FDA hold McKesson accountable for the problems we have encountered in the administration of the program?

I had called Clozapine REMS to inform them that they had mistakenly sent me a notice that a former patient no longer under my care is overdue for the required blood test.

I left a message with FDA to report this apparent communication breakdown. I will report in a future post how (or whether) FDA responds.

I hope the call center representative did not just slip up, and that her admission represents change to a policy of increased openness.

Add a comment
QR code


Daily Tweets

Notable Person: #BHCPOD
Phobia: #BNphobia

National Conference Tweetchats

2/22-26: ACPsych


Connect with us